Easing the transition to insulin therapy in people with type 2 diabetes

Diabetes Educator

Volumn 33, Issue SUPPL. 7, 2007, Pages

  Blonde, Lawrence ^a  

^a OCHSNER CLINIC FOUNDATION   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIDIABETIC AGENT; INSULIN;

ARTICLE; ATTITUDE TO HEALTH; DRUG COMBINATION; GLUCOSE BLOOD LEVEL; HUMAN; METABOLISM; NON INSULIN DEPENDENT DIABETES MELLITUS; PANCREAS ISLET BETA CELL; PATHOPHYSIOLOGY; PSYCHOLOGICAL ASPECT; SECRETION;

ATTITUDE TO HEALTH; BLOOD GLUCOSE; DIABETES MELLITUS, TYPE 2; DRUG THERAPY, COMBINATION; HUMANS; HYPOGLYCEMIC AGENTS; INSULIN; INSULIN-SECRETING CELLS;

EID: 34547661691     PISSN: 01457217     EISSN: 15546063     Source Type: Journal    
DOI: 10.1177/0145721707305695     Document Type: Article

References (27)

1. Brunzell JD, Robertson RP, Lerner RL, et al. Relationships between fasting plasma glucose levels and insulin secretion during intravenous glucose tolerance tests. J Clin Endocrinol Metab. 1976 ; 42: 222-229.
2. UK Prospective Diabetes Study Group. UK Prospective Diabetes Study 16: overview of 6 years' therapy of type II diabetes: a progressive disease. Diabetes. 1995 ; 44: 1249-1258.
3. Ryan EA, Imes S., Wallace C. Short-term intensive insulin therapy in newly diagnosed type 2 diabetes. Diabetes Care. 2004 ; 27: 1028-1032.
4. Alvarsson M., Sundkvist G., Lager I., et al. Beneficial effects of insulin versus sulphonylurea on insulin secretion and metabolic control in recently diagnosed type 2 diabetic patients. Diabetes Care. 2003 ; 26: 2231-2237.
5. Li Y., Xu W., Liao Z., et al. Induction of long-term glycemic control in newly diagnosed type 2 diabetic patients is associated with improvement of beta-cell function. Diabetes Care. 2004 ; 27: 2597-2602.
6. Colagiuri S., Cull CA, Holman RR ; UKPDS Group. Are lower fasting plasma glucose levels at diagnosis of type 2 diabetes associated with improved outcomes? Diabetes Care. 2002 ; 25: 1410-1417.
7. Cook MN, Girman CJ, Stein PP, Alexander CM, Holman RR Glycemic control continues to deteriorate after sulfonylureas are added to metformin among patients with type 2 diabetes. Diabetes Care. 2005 ; 28: 995-1000.
8. DeFronzo RA, Goodman AM Efficacy of metformin in patients with non-insulin-dependent diabetes mellitus. The Multicenter Metformin Study Group. N Engl J Med. 1995 ; 333: 541-549.
9. Fonseca V., Rosenstock J., Patwardhan R., Salzman A. Effect of metformin and rosiglitazone combination therapy in patients with type 2 diabetes mellitus: a randomized controlled trial. JAMA. 2000 ; 283: 1695-1702.
10. Kipnes MS, Krosnick A., Rendell MS, Egan JW, Mathisen AL, Schneider RL Pioglitazone hydrochloride in combination with sulfonylurea therapy improves glycemic control in patients with type 2 diabetes mellitus: a randomized, placebo-controlled study. Am J Med. 2001 ; 111: 10-17.
11. Rosenstock J., Sugimoto D., Strange P., Stewart JA, Soltes-Rak E., Dailey G. Triple therapy in type 2 diabetes: insulin glargine or rosiglitazone added to combination therapy of sulfonylurea plus metformin in insulin-naive patients. Diabetes Care. 2006 ; 29: 554-559.
12. Brown JB, Nichols GA, Perry A. The burden of treatment failure in type 2 diabetes. Diabetes Care. 2004 ; 27: 1535-1540.
13. Riddle MC, Rosenstock J., Gerich J. The treat-to-target trial: randomized addition of glargine or human NPH insulin to oral therapy of type 2 diabetic patients. Diabetes Care. 2003 ; 26: 3080-3086.
14. Janka HU, Plewe G., Riddle MC, Kliebe-Frisch C., Schweitzer MA, Yki-Jarvinen H. Comparison of basal insulin added to oral agents versus twice-daily premixed insulin as initial insulin therapy for type 2 diabetes. Diabetes Care. 2005 ; 28: 254-259.
15. Raskin P., Allen E., Hollander P., et al. Initiating insulin therapy in type 2 diabetes: a comparison of biphasic and basal insulin analogs. Diabetes Care. 2005 ; 28: 260-265.
16. Riddle MC The underuse of insulin therapy in North America. Diabetes Metab Res Rev. 2002 ; 18 (suppl 3). S42 - S49.
17. Aviles-Santa L., Sinding J., Raskin P. Effects of metformin in patients with poorly controlled, insulin-treated type 2 diabetes mellitus: a randomized, double-blind, placebo-controlled trial. Ann Intern Med. 1999 ; 131: 182-188.
18. Yki-Jarvinen H., Ryysy L., Nikkila K., Tulokas T., Vanamo R., Heikkila M. Comparison of bedtime insulin regimens in patients with type 2 diabetes mellitus: a randomized, controlled trial. Ann Intern Med. 1999 ; 130: 389-396.
19. Bergenstal R., Johnson M., Whipple D., et al. Advantages of adding metformin to multiple dose insulin therapy in type 2 diabetes. Diabetes. 1998 ; 47 (suppl 1). A89.
20. Dandona P., Aljada A., Chaudhuri A., Bandyopadhyay A. The potential influence of inflammation and insulin resistance on the pathogenesis and treatment of atherosclerosis-related complications in type 2 diabetes. J Clin Endocrinol Metab. 2003 ; 88: 2422-2429.
21. Malmberg K., Ryden L., Efendic S., et al. Randomized trial of insulin-glucose infusion followed by subcutaneous insulin treatment in diabetic patients with acute myocardial infarction (DIGAMI study): effects on mortality at 1 year. J Am Coll Cardiol. 1995 ; 26: 57-65.
22. UK Prospective Diabetes Study (UKPDS) Group. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). Lancet. 1998 ; 352: 854-865.
23. Van den Berghe G., Wouters P., Weekers F., et al. Intensive insulin therapy in critically ill patients. N Engl J Med. 2001 ; 345: 1359-1367.
24. Nathan DM, Buse JB, Davidson MB, et al. Management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement from the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care. 2006 ; 29: 1963-1972.
25. The American Diabetes Association. 2007 resource guide: a supplement to Diabetes Forecast. Insulins; RG13-RG18. Diabetes Forecast. Available at: http://www.diabetes.org/diabetes-forecast/RG07/RG07Insulin.pdf. Accessed January 11, 2007.
26. Bretzel RG, Linn T. Equivalence of basal insulin glargine vs prandial insulin lispro for glucose control in type 2 diabetes patients on oral agents-results of the APOLLO study. Diabetes. 2006 ; 55 (suppl 1):A 76. Abstract 326-OR.
27. Kazda C., Hulstrunk H., Helsberg K., Langer F., Forst T., Hanefeld M. Prandial insulin substitution with insulin lispro or insulin lispro mid mixture vs. basal therapy with insulin glargine: a randomized controlled trial in patients with type 2 diabetes beginning insulin therapy. J Diabetes Complicat. 2006 ; 20: 145-152.